Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 19,39€(+32,81%). Der Median liegt bei 19,39€(+32,81%).
Kaufen | 1 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Dividenden-Strategie | 0 / 15 |
HGI-Strategie | 6 / 18 |
Levermann-Strategie | -1 / 13 |
News
New Strong Sell Stocks for May 28th
BCC, DOOO and CMT have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2025.» Mehr auf zacks.com
Core Molding Technologies Publishes Its 3rd Annual Sustainability Report
COLUMBUS, Ohio, May 22, 2025 (GLOBE NEWSWIRE) -- Core Molding Technologies, Inc. (NYSE American: CMT) (“Core Molding”, “Core” or the “Company”), a leading engineered materials company specializing in molded structural products, principally in building products, industrial and utilities, medium and heavy-duty truck and powersports industries across the United States, Canada and Mexico today announced the release of its third annual Sustainability Report, which highlights the Company's ongoing commitment to responsible business practices, community engagement, and environmental stewardship.» Mehr auf globenewswire.com
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in CMT-SORD-Null rats demonstrated a highly statistically significant 37% (p=0.005) reduction of sorbitol in the sciatic nerve, the tissue of interest, after treatment with govorestat.Reflective of the peripheral neuropathy experienced by patients with CMT-SORD. Govorestat remains generally safe and well tolerated Company remains committed to potential NDA submission of govorestat for treatment of CMT-SORD in 2025 NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare disease, today presented full 12-month clinical results and new topline data from 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for the treatment of Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease, in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, being held May 17-20, 2025 in Edinburgh, Scotland.» Mehr auf globenewswire.com
Historische Dividenden
Alle Dividenden KennzahlenUnternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 56,80 Mio | 21,56% |
Bruttoeinkommen | 10,89 Mio | 8,74% |
Nettoeinkommen | 2,02 Mio | 42,06% |
EBITDA | 5,70 Mio | 25,75% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 126,47 Mio€ |
Anzahl Aktien | 8,99 Mio |
52 Wochen-Hoch/Tief | 17,44€ - 10,80€ |
Dividenden | Nein |
Beta | 1,03 |
KGV (PE Ratio) | 11,74 |
KGWV (PEG Ratio) | −1,00 |
KBV (PB Ratio) | 0,92 |
KUV (PS Ratio) | 0,50 |
Unternehmensprofil
Core Molding Technologies, Inc. ist zusammen mit seinen Tochtergesellschaften in der Herstellung von thermoplastischen und duroplastischen Strukturprodukten tätig. Das Unternehmen bietet eine Reihe von Herstellungsverfahren an, zu denen das Formpressen von Folien, das Harzinjektionsverfahren, das Flüssiggießen von Dicyclopentadien, das Aufsprühen und Auflegen von Hand, die direkte Verarbeitung von Langfaser-Thermoplasten sowie das Spritzgießen von Strukturschaum und Strukturgewebe gehören. Das Unternehmen beliefert verschiedene Märkte, darunter mittelschwere und schwere Lastkraftwagen, Automobile, Motorsport, Bauwesen, Landwirtschaft, Bauprodukte und andere kommerzielle Märkte in den Vereinigten Staaten, Mexiko, Kanada und international. Das Unternehmen war früher als Core Materials Corporation bekannt und änderte im August 2002 seinen Namen in Core Molding Technologies, Inc. Core Molding Technologies, Inc. wurde 1996 gegründet und hat seinen Hauptsitz in Columbus, Ohio.
Name | Core Molding Technologies |
CEO | David L. Duvall |
Sitz | Columbus, oh USA |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 1.570 |
Ticker Symbole
Börse | Symbol |
---|---|
AMEX | CMT |
Frankfurt | XQN.F |
Assets entdecken
Shareholder von Core Molding Technologies investieren auch in folgende Assets